Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

Spyre Therapeutics, Inc.

First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.
Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).
Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.
Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.